scholarly journals Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases

2013 ◽  
Vol 7 (2) ◽  
pp. 357-360 ◽  
Author(s):  
FUMIHIRO YAMAGUCHI ◽  
KUNIHIKO FUKUCHI ◽  
YOHEI YAMAZAKI ◽  
HIROMI TAKAYASU ◽  
SAKIKO TAZAWA ◽  
...  
Oncotarget ◽  
2018 ◽  
Vol 9 (20) ◽  
pp. 15418-15434 ◽  
Author(s):  
Carina Heydt ◽  
Sebastian Michels ◽  
Kenneth S. Thress ◽  
Sven Bergner ◽  
Jürgen Wolf ◽  
...  

RSC Advances ◽  
2018 ◽  
Vol 8 (70) ◽  
pp. 40387-40394 ◽  
Author(s):  
Mohamed W. Attwa ◽  
Adnan A. Kadi ◽  
Hany W. Darwish ◽  
Ali S. Abdelhameed

Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).


Sign in / Sign up

Export Citation Format

Share Document